Sang‑hyu Nam

Head of Department, Naeun Hospital (Advisory)

Therapeutic Areas

Drug	Indication	Phase
Dr. Noon CVD	Cardiovascular disease risk prediction	Regulatory Approved
Dr. Noon Fundus	Glaucoma, cataract, and retinal disease diagnosis	Regulatory Approved
Retinal AI for CKD	Chronic kidney disease risk assessment	Research/Pre‑clinical
Retinal AI for NAFLD	Non‑alcoholic fatty liver disease risk assessment	Research/Pre‑clinical
Retinal AI for Neurodegeneration	Early detection of neurodegenerative risk	Research/Pre‑clinical